An observational study in Covid19, sponsored by European Society for Emergency Medicine (EUSEM) Research Network. Status unknown at 5 sites in 5 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2020-12-24.
Sponsored by European Society for Emergency Medicine (EUSEM) Research Network · Observational
This project is an unfunded collaboration of approximately 30 emergency departments across Europe led by the EUSEM research network. It involves collection of data in relation to determining the epidemiology and outcome of adult patients who present to emergency departments with a suspected Covid infection.
Over the past 6 months, the world has faced a novel infection disease outbreak, due to a novel coronavirus, the severe acute respiratory syndrome coronavirus (SARS-CoV2), with a massive impact on healthcare resource.
In Europe, numbers of confirmed cases continue to rise. Europe is currently one of the regions with the highest number of Covid-19 cases and deaths due to this emergent diseases.
Most COVID-19 infected patients present with mild to moderate acute respiratory symptoms, including cough, fever, dyspnea and pneumonia. About 20% will present with severe or critical manifestations of the disease, including pneumonia, respiratory failure and acute respiratory distress syndrome (ARDS).
Anticipating the needs for hospitalization in ward and/or intensive care is crucial.
Emergency departments are at the front line for triaging patients with suspected Covid-19 and referring them to the appropriate level of care.
In Europe, the number of ED patients with suspected Covid-19 is variable; rate of hospitalization from ED reaches 40% for this population.
Risk stratification and management decisions of patients presenting to the ED with suspected COVID-19 is a challenge for emergency physicians.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's planned enrollment of 8,000 is above the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →This is the only study on the registry with European Society for Emergency Medicine (EUSEM) Research Network as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
hospitalization
hospitalization after ED visit
Time frame: 30 days
length of hospital stay
Hospital LOS
Time frame: 30 days
in-hospital mortality
Death during hospitalization
Time frame: 30 days
ICU admission
ICU admission after ED visit
Time frame: 30 days
This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.